21 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Study Attrition and AdherencePrimary· Up to 3 weeks from registration
Study participants kept a daily log where they listed the dates and times they used the light visor - noting time they put it on, and the time they took it off. The light exposure were recorded to assess adherence to the treatment protocol.
Adherence: percentage that the study participant used the light visor for 30 minutes per day during the 14-day light therapy intervention (based on the daily log that reported use or not use of the light visor for 30 minutes for the 14 days of the intervention and the time they put it on each day and took it off each day)
Attrition: study participants wit
Attrition
Group
Value
95% CI
Arm 1: Bright Blue-green Light
1
Arm 2: Dim Red Light
1
Adherence to light therapy
Group
Value
95% CI
Arm 1: Bright Blue-green Light
14
Arm 2: Dim Red Light
14
Effects of Bright Light on Sleep Disturbance as Measured by the PROMIS-Sleep DisturbanceSecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep disturbance T-Score.
A higher PROMIS-Sleep disturbance T-score represents greater\\worse sleep disturbance.
PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.
Higher scores mean worse sleep disturbance
Note: For negatively-worded concepts like Fatigue, a T-score of 60 is one SD worse than average. By comparison, a Fatigue T-score of 40 is one SD better than average.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
56
± 6
Arm 2: Dim Red Light
57.3
± 7.5
Post-Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
49.6
± 5.3
Arm 2: Dim Red Light
50.4
± 6
Effects of Bright Light on Sleep Disturbance as Measured by the PSQISecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Pittsburgh Sleep Quality Index (PSQI) Global score:
The PSQI has 7 components, with each component self-rated from 0-3, with 3 being worse sleep quality. Global PSQI sleep score is the sum of all 7 components, with score range from 0-21, with higher score meaning worse sleep quality.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
9.3
± 3.2
Arm 2: Dim Red Light
9.6
± 3.2
Post-Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
7.8
± 2.4
Arm 2: Dim Red Light
6.0
± 3.1
Effects of Bright Light on Fatigue as Measured by the PROMIS-Cancer-FatigueSecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue T-Score.
A higher PROMIS-Cancer-Fatigue T-score represents greater\\worse fatigue.
PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.
Higher scores mean worse fatigue
Note: For negatively-worded concepts like Fatigue, a T-score of 60 is one SD worse than average. By comparison, a Fatigue T-score of 40 is one SD better than average.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
55.8
± 6.8
Arm 2: Dim Red Light
56.3
± 7.9
Post Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
48.3
± 4.4
Arm 2: Dim Red Light
50.5
± 6.4
Effects of Bright Light on Fatigue as Measured by the Daily LogSecondary· Kept throughout the approx 3 weeks of the study
Fatigue self-report is rated numerically from 1-5, with greater score meaning more fatigue
Baseline self-reported fatigue
Group
Value
95% CI
Arm 1: Bright Blue-green Light
3.54
± 2.03
Arm 2: Dim Red Light
4.57
± 2.41
Post-Test self-reported fatigue
Group
Value
95% CI
Arm 1: Bright Blue-green Light
1.92
± 1.44
Arm 2: Dim Red Light
2.86
± 2.35
Effects of Bright Light on Depression as Measured by the PROMIS-DepressionSecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression T-Score.
A higher PROMIS-Depression T-score represents greater\\worse Depression.
PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.
Higher scores mean worse worse depression.
Note: For negatively-worded concepts like Fatigue, a T-score of 60 is one SD worse than average. By comparison, a Fatigue T-score of 40 is one SD better than average.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
50.4
± 7.9
Arm 2: Dim Red Light
51.1
± 6.4
Post-Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
45.2
± 5.9
Arm 2: Dim Red Light
46.5
± 7.0
Effects of Bright Light on Depression as Measured by the CES-DSecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Center for Epidemiologic Studies Depression Scale (CES-D) score:
Total CES-D range is 0-60, with higher score meaning more depressed.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
14.7
± 8.3
Arm 2: Dim Red Light
16.3
± 4.1
Post-Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
6.0
± 3.8
Arm 2: Dim Red Light
8.9
± 5.3
Effects of Bright Lights on Cognitive Dysfunction as Measured by the MoCASecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
MoCA (Montreal Cognitive Assessment):
Test conducted by researcher, with total score range 0-30. Higher score means less cognitive dysfunction.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
27.9
± 1.7
Arm 2: Dim Red Light
26.6
± 2.2
Post-Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
28.0
± 2.0
Arm 2: Dim Red Light
27.1
± 1.7
Effect of Bright Light on Quality of Life as Measured by the PROMIS-Physical FunctionSecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function T-Score.
A higher PROMIS-Physical Function T-score represents greater\\better Physical Function.
PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.
Higher scores mean better functioning.
Note: A T-score of 60 is one SD greater than average; A T-Score of 40 is one SD lower than average.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
47.5
± 10.2
Arm 2: Dim Red Light
48.6
± 8.1
Post-Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
48.7
± 9.2
Arm 2: Dim Red Light
51.3
± 8.3
Effect of Bright Light on Quality of Life as Measured by EORTC QLQ-30Secondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Quality of Life (QOL)-Global Health score: Range 0-100, higher score is better global health quality of life Quality of Life (QOL) Symptom score: Range 0-100, Higher score is worse symptoms quality of life Quality of Life (QOL)-Function: Range 0-100, Higher score is better functional quality of life
Baseline QOL-Global
Group
Value
95% CI
Arm 1: Bright Blue-green Light
65.6
± 16.6
Arm 2: Dim Red Light
76.1
± 16.0
Post-Test QOL-Global
Group
Value
95% CI
Arm 1: Bright Blue-green Light
76.2
± 7.9
Arm 2: Dim Red Light
81.0
± 11
Baseline QOL-Symptom
Group
Value
95% CI
Arm 1: Bright Blue-green Light
20.7
± 13.0
Arm 2: Dim Red Light
19.5
± 9.0
Post-Test QOL-Symptom
Group
Value
95% CI
Arm 1: Bright Blue-green Light
13.4
± 7.1
Arm 2: Dim Red Light
12.1
± 7.3
Baseline QOL-Function
Group
Value
95% CI
Arm 1: Bright Blue-green Light
76.7
± 15.7
Arm 2: Dim Red Light
80.4
± 10.4
Post-Test QOL-Function
Group
Value
95% CI
Arm 1: Bright Blue-green Light
87.0
± 6.6
Arm 2: Dim Red Light
87.6
± 9.2
Effects of Bright Light on Level of Stress as Measured by the PSG-Total Sleep TimeSecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Objective testing using in-lab polysomnography (PSG) is used to measure the effects of bright light on level of stress. Minutes of total sleep time is reported.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
394.2
± 68.9
Arm 2: Dim Red Light
393.53
± 59.35
Post-Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
386.1
± 84.8
Arm 2: Dim Red Light
415.9
± 71.5
Effects of Bright Light on Level of Stress as Measured by the PSG-Sleep EfficiencySecondary· Baseline (day 2 of study) and Post-treatment (approx day 17 of study)
Objective testing using in-lab polysomnography (PSG)is used to measure the effects of bright light on level of stress. Sleep efficiency is reported as percentage of total sleep time.
Baseline
Group
Value
95% CI
Arm 1: Bright Blue-green Light
81.9
± 7.9
Arm 2: Dim Red Light
82.7
± 8.08
Post-Test
Group
Value
95% CI
Arm 1: Bright Blue-green Light
81.0
± 14.3
Arm 2: Dim Red Light
82.4
± 12.2
Adverse events — posted to ClinicalTrials.gov
Time frame: Baseline assessment through post-assessment (up to 3 weeks).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study will implement therapeutic bright light that is tailored to the individual's circadian typology and will estimate its effects on circadian rhythms, 4 common cancer-associated symptoms, and impact on quality of life in survivors living with cancer. Examining a selected phase marker (core body temperature) in relation to the associated clinical features (symptoms) is the starting point for future investigation of the biological mechanisms of symptoms.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07175246 — Exploring the Patterns of Sleep Disordered Breathing in Systemic Sclerosis Patients
· not yet recruiting
NCT07061990 — The Role of Inflammatory Markers in OSAHS-Related White Matter Lesions and Asymptomatic Lacunar Infarction
· completed
NCT05102474 — Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis
· completed
NCT03210675 — Early Detection and Treatment of Respiratory Sleep Disorders in Children With Down Syndrome
· NA
· unknown
NCT00501215 — Effect of Parathyroidectomy on Sleep
· NA
· completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
NCT06148038 — CBD for Breast Cancer Primary Tumors
· Phase 1
· recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
· Phase 2
· recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
· Phase 2
· recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer
· NA
· recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
· Phase 2
· recruiting
Other Michigan State University trials
Trials by the same sponsor.
NCT06325150 — The Impact of Light Exposure on Cognitive Function in Classrooms
· Phase 1
· not yet recruiting
NCT07213284 — Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial
· NA
· not yet recruiting
NCT07164391 — Empowering Vietnamese Americans
· NA
· not yet recruiting
NCT04521972 — Impact of Room Light on Uterine Contractions and Labor Progression in Pregnancy
· NA
· recruiting
NCT05358964 — Family Health Histories: Creating a Culturally Tailored Tool to Reduce Health Disparities in the Black Community
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michigan State University
Last refreshed: 10 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03304587.